Format

Send to

Choose Destination
J Biomed Sci. 2017 Sep 9;24(1):71. doi: 10.1186/s12929-017-0377-1.

Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine.

Author information

1
Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA. bjh82@case.edu.
2
Department of Anatomy and Anthropology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
3
Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA.
4
Aristea Translational Medicine, Park City, UT, USA.
5
Department of Neurosurgery, Taipei Medical University, Taipei, Taiwan.
6
Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.

Abstract

Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality of both young adults of less than 45 years of age and the elderly, and contributes to about 30% of all injury deaths in the United States of America. Whereas there has been a significant improvement in our understanding of the mechanism that underpin the primary and secondary stages of damage associated with a TBI incident, to date however, this knowledge has not translated into the development of effective new pharmacological TBI treatment strategies. Prior experimental and clinical studies of drugs working via a single mechanism only may have failed to address the full range of pathologies that lead to the neuronal loss and cognitive impairment evident in TBI and other disorders. The present review focuses on two drugs with the potential to benefit multiple pathways considered important in TBI. Notably, both agents have already been developed into human studies for other conditions, and thus have the potential to be rapidly repositioned as TBI therapies. The first is N-acetyl cysteine (NAC) that is currently used in over the counter medications for its anti-inflammatory properties. The second is (-)-phenserine ((-)-Phen) that was originally developed as an experimental Alzheimer's disease (AD) drug. We briefly review background information about TBI and subsequently review literature suggesting that NAC and (-)-Phen may be useful therapeutic approaches for TBI, for which there are no currently approved drugs.

KEYWORDS:

N-acetyl cysteine; Phenserine; Traumatic brain injury

PMID:
28886718
PMCID:
PMC5591517
DOI:
10.1186/s12929-017-0377-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center